Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.

Oncoimmunology · 2021 · PMC8096334 · PMID 33996267

Europe PMC DOI

hedged sentence

0.0583

closest p · 1.2× alpha

0.0583

boldest claim

The sentences

trending toward significancep = .0583so close (0.05 < p ≤ 0.1)

administration of bintrafusp alfa, with values trending toward significance ( p = .0583) upon s.c. injection.

also in 580 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.